COVID-19-Related Outcomes Among Group Home Residents with Serious Mental Illness in Massachusetts in the First Year of the Pandemic.

COVID-19 Congregate living environments Group homes Serious mental illness

Journal

Administration and policy in mental health
ISSN: 1573-3289
Titre abrégé: Adm Policy Ment Health
Pays: United States
ID NLM: 8914574

Informations de publication

Date de publication:
08 Nov 2023
Historique:
accepted: 06 10 2023
medline: 8 11 2023
pubmed: 8 11 2023
entrez: 8 11 2023
Statut: aheadofprint

Résumé

This study examined COVID-19 infection and hospitalizations among people with serious mental illness who resided in residential care group homes in Massachusetts during the first year of the COVID-19 pandemic. The authors analyzed data on 2261 group home residents and COVID-19 data from the Massachusetts Department of Public Health. Outcomes included positive COVID-19 tests and COVID-19 hospitalizations March 1, 2020-June 30, 2020 (wave 1) and July 1, 2020-March 31, 2021 (wave 2). Associations between hazard of outcomes and resident and group home characteristics were estimated using multi-level Cox frailty models including home- and city-level frailties. Between March 2020 and March 2021, 182 (8%) residents tested positive for COVID-19, and 51 (2%) had a COVID-19 hospitalization. Compared with the Massachusetts population, group home residents had age-adjusted rate ratios of 3.0 (4.86 vs. 1.60 per 100) for COVID infection and 13.5 (1.99 vs. 0.15 per 100) for COVID hospitalizations during wave 1; during wave 2, the rate ratios were 0.5 (4.55 vs. 8.48 per 100) and 1.7 (0.69 vs. 0.40 per 100). In Cox models, residents in homes with more beds, higher staff-to-resident ratios, recent infections among staff and other residents, and in cities with high community transmission risk had greater hazard of COVID-19 infection. Policies and interventions that target group home-specific risks are needed to mitigate adverse communicable disease outcomes in this population.Clinical Trial Registration Number This study provides baseline (i.e., pre-randomization) data from a clinical trial study NCT04726371.

Identifiants

DOI: 10.1007/s10488-023-01311-9 PMID: 37938475
pubmed: 37938475
doi: 10.1007/s10488-023-01311-9
pii: 10.1007/s10488-023-01311-9
doi:

Banques de données

ClinicalTrials.gov
['NCT04726371']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Patient-Centered Outcomes Research Institute
ID : COVID-2020C2-10803
Pays : United States

Informations de copyright

© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Références

Austin, P. C., Wagner, P., & Merlo, J. (2017). The median hazard ratio: A useful measure of variance and general contextual effects in multilevel survival analysis. Statistics in Medicine, 36, 928–938.
doi: 10.1002/sim.7188 pubmed: 27885709
Barcella, C. A., Polcwiartek, C., Mohr, G. H., et al. (2021). Severe mental illness is associated with increased mortality and severe course of COVID-19. Acta Psychiatrica Scandinavica, 144, 82–91.
doi: 10.1111/acps.13309 pubmed: 33894064 pmcid: 8250986
CDC. (2020). Coronavirus Disease 2019 (COVID-19). Centers for Disease Control and Prevention. https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/indicators-monitoring-community-levels.html
CDC. (2022). People with Certain Medical Conditions. Centers for Disease Control and Prevention. https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html
Chen, M. K., Chevalier, J. A., & Long, E. F. (2021). Nursing home staff networks and COVID-19. Proceedings of the National Academy of Sciences, 118, e2015455118.
doi: 10.1073/pnas.2015455118
De Hert, M., Mazereel, V., Stroobants, M., et al. (2022). COVID-19-related mortality risk in people with severe mental illness: A systematic and critical review. Front Psychiatry, 12, 798554. https://doi.org/10.3389/fpsyt.2021.798554
doi: 10.3389/fpsyt.2021.798554 pubmed: 35095612 pmcid: 8793909
Figueroa, J. F., Wadhera, R. K., Lee, D., et al. (2020a). Community-level factors associated with racial and ethnic disparities in COVID-19 rates in Massachusetts. Health Affairs, 39, 1984–1992.
doi: 10.1377/hlthaff.2020.01040 pubmed: 32853056
Figueroa, J. F., Wadhera, R. K., Papanicolas, I., et al. (2020b). Association of nursing home ratings on health inspections, quality of care, and nurse staffing with COVID-19 cases. JAMA, 324, 1103–1105.
doi: 10.1001/jama.2020.14709 pubmed: 32790822 pmcid: 7418040
Fond, G., Pauly, V., Leone, M., et al. (2021). Disparities in intensive care unit admission and mortality among patients with schizophrenia and COVID-19: A National cohort study. Schizophrenia Bulletin, 47, 624–634.
doi: 10.1093/schbul/sbaa158 pubmed: 33089862
Gorges, R. J., & Konetzka, R. T. (2020). Staffing levels and COVID-19 cases and outbreaks in U.S. nursing homes. Journal of the American Geriatrics Society, 68, 2462–2466.
doi: 10.1111/jgs.16787 pubmed: 32770832 pmcid: 7436613
Hakim D. (2020). ‘It’s Hit Our Front Door’: Homes for the disabled see a surge of Covid-19. The New York Times. https://www.nytimes.com/2020/04/08/nyregion/coronavirus-disabilities-group-homes.html
Hege, A., Lane, S., Spaulding, T., et al. (2022). County-level social determinants of health and COVID-19 in nursing homes, United States, June 1, 2020–January 31, 2021. Public Health Reports, 137, 137–148.
doi: 10.1177/00333549211053666 pubmed: 34788163
Janssen, E. M., McGinty, E. E., Azrin, S. T., et al. (2015). Review of the evidence: Prevalence of medical conditions in the United States population with serious mental illness. General Hospital Psychiatry, 37, 199–222.
doi: 10.1016/j.genhosppsych.2015.03.004 pubmed: 25881768 pmcid: 4663043
KFF. (2022). Over 200,000 residents and staff in long-term care facilities have died from COVID-19. https://www.kff.org/policy-watch/over-200000-residents-and-staff-in-long-term-care-facilities-have-died-from-covid-19/
Konetzka, R. T., White, E. M., Pralea, A., et al. (2021). A systematic review of long-term care facility characteristics associated with COVID-19 outcomes. Journal of the American Geriatrics Society, 69, 2766–2777.
doi: 10.1111/jgs.17434 pubmed: 34549415 pmcid: 8631348
Kozloff, N., Mulsant, B. H., Stergiopoulos, V., et al. (2020). The COVID-19 global pandemic: Implications for people with schizophrenia and related disorders. Schizophrenia Bulletin, 46, 752–757.
doi: 10.1093/schbul/sbaa051 pubmed: 32343342 pmcid: 7197583
Lane, S. J., Sugg, M., Spaulding, T. J., et al. (2022). Southeastern United States predictors of COVID-19 in nursing homes. Journal of Applied Gerontology, 41, 1641–1650.
doi: 10.1177/07334648221082022 pubmed: 35412383
Lee, R. M., Handunge, V. L., Augenbraun, S. L., et al. (2022). Addressing COVID-19 testing inequities among underserved populations in Massachusetts: A rapid qualitative exploration of health center staff, partner, and resident perceptions. Frontiers in Public Health, 10, 838544.
doi: 10.3389/fpubh.2022.838544 pubmed: 35400042 pmcid: 8987278
Levison J. H., Krane, D., Donelan, K., Aschbrenner, K., Trieu, H.D., Chau, C., Wilson, A., Oreskovic, N.M., Irwin, K., Iezzoni, L.I., Xie, H., Samuels, R., Silverman, P., Batson, J., Fathi, A., Gamse, S., Holland, S., Wolfe, J., Shellenberger, K., Cella, E., Bird, B., Skotko, B.G., Bartels, S. (2023) Best practices to reduce COVID-19 in group homes for individuals with serious mental illness and intellectual and developmental disabilities: Protocol for a hybrid type 1 effectiveness-implementation cluster randomized trial. Contemporary Clinical Trials, 125, 107053. https://doi.org/10.1016/j.cct.2022.107053
doi: 10.1016/j.cct.2022.107053 pubmed: 36539061
Mass.gov. (2023). COVID-19 Response Reporting | Massachusetts Department of Public Health. https://www.mass.gov/info-details/covid-19-response-reporting#covid-19-interactive-data-dashboard
McGarry, B. E., Grabowski, D. C., & Barnett, M. L. (2020). Severe staffing and personal protective equipment shortages faced by nursing homes during the COVID-19 pandemic. Health Affaies, 39, 1812–1821.
doi: 10.1377/hlthaff.2020.01269
Mehta, H. B., Li, S., & Goodwin, J. S. (2021). Risk factors associated with SARS-CoV-2 infections, hospitalization, and mortality among US nursing home residents. JAMA Network Open, 4, e216315.
doi: 10.1001/jamanetworkopen.2021.6315 pubmed: 33787905 pmcid: 8013796
Moretti, F., Visentin, D., Bovolenta, E., et al. (2020). Attitudes of nursing home staff towards influenza vaccination: Opinions and factors influencing hesitancy. International Journal of Environmental Research and Public Health, 17, 1851.
doi: 10.3390/ijerph17061851 pubmed: 32178426 pmcid: 7143910
Nemani, K., Li, C., Olfson, M., et al. (2021). Association of psychiatric disorders with mortality among patients With COVID-19. JAMA Psychiatry, 78, 380–386.
doi: 10.1001/jamapsychiatry.2020.4442 pubmed: 33502436
Ng, H. K. T., Filardo, G., & Zheng, G. (2008). Confidence interval estimating procedures for standardized incidence rates. Computational Statistics & Data Analysis, 52, 3501–3516.
doi: 10.1016/j.csda.2007.11.004
Novak, P., Sanmartin, M. X., Ali, M. M., et al. (2021). Health conditions associated with severe illness from COVID-19 among individuals with serious mental illness. Psychiatric Services, 72, 468–469.
doi: 10.1176/appi.ps.202000300 pubmed: 33208029
Olfson, M., Gerhard, T., Huang, C., et al. (2015). Premature mortality among adults with schizophrenia in the United States. JAMA Psychiatry, 72(1172–1181), 2015.
Shang, J., Harrison, J. M., Chastain, A. M., et al. (2022). Influenza vaccination of home health care staff and the impact on patient hospitalizations. American Journal of Infection Control, 50, 369–374.
doi: 10.1016/j.ajic.2021.12.027 pubmed: 35369936 pmcid: 9052587
Shinn, A. K., & Viron, M. (2020). Perspectives on the COVID-19 pandemic and individuals with serious mental illness. Journal of Clinical Psychiatry, 81, 14205.
The New York Times. (2020). Nearly one-third of U.S. coronavirus deaths are linked to nursing homes. https://www.nytimes.com/interactive/2020/us/coronavirus-nursing-homes.html
Therneau TM. (2022). coxme: Mixed Effects Cox Models, 2022. https://CRAN.R-project.org/package=coxme
Therneau, T. M., & Grambsch, P. M. (2000). Frailty models. In T. M. Therneau & P. M. Grambsch (Eds.), Modeling survival data: Extending the cox model. Springer. https://doi.org/10.1007/978-1-4757-3294-8_9
doi: 10.1007/978-1-4757-3294-8_9
Tung, E. L., Peek, M. E., Rivas, M. A., et al. (2021). Association of neighborhood disadvantage with racial disparities In COVID-19 positivity in chicago. Health Affairs, 40, 1784–1791.
doi: 10.1377/hlthaff.2021.00695 pubmed: 34724418
Vai, B., Mazza, M. G., Delli Colli, C., et al. (2021). Mental disorders and risk of COVID-19-related mortality, hospitalisation, and intensive care unit admission: A systematic review and meta-analysis. Lancet Psychiatry, 8, 797–812.
doi: 10.1016/S2215-0366(21)00232-7 pubmed: 34274033 pmcid: 8285121
Walker, E. R., McGee, R. E., & Druss, B. G. (2015). Mortality in mental disorders and global disease burden implications: A systematic review and meta-analysis. JAMA Psychiatry, 72, 334–341.
doi: 10.1001/jamapsychiatry.2014.2502 pubmed: 25671328 pmcid: 4461039
Wang, Q., Xu, R., & Volkow, N. D. (2021). Increased risk of COVID-19 infection and mortality in people with mental disorders: Analysis from electronic health records in the United States. World Psychiatry, 20, 124–130.
doi: 10.1002/wps.20806 pubmed: 33026219

Auteurs

Vicki Fung (V)

Mongan Institute, Massachusetts General Hospital, Harvard Medical School, 100 Cambridge Street, Suite 1600, Boston, MA, 02114, USA. vfung@mgh.harvard.edu.
Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. vfung@mgh.harvard.edu.
ORCID: 0000-0001-8078-5431

Julie H Levison (JH)

Mongan Institute, Massachusetts General Hospital, Harvard Medical School, 100 Cambridge Street, Suite 1600, Boston, MA, 02114, USA.
Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Division of General Internal Medicine, Massachusetts General Hospital, Boston, MA, USA.

Anna Wilson (A)

Mongan Institute, Massachusetts General Hospital, Harvard Medical School, 100 Cambridge Street, Suite 1600, Boston, MA, 02114, USA.

David Cheng (D)

Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Biostatistics Center, Massachusetts General Hospital, Boston, MA, USA.

Cindy Chau (C)

Mongan Institute, Massachusetts General Hospital, Harvard Medical School, 100 Cambridge Street, Suite 1600, Boston, MA, 02114, USA.

David Krane (D)

Mongan Institute, Massachusetts General Hospital, Harvard Medical School, 100 Cambridge Street, Suite 1600, Boston, MA, 02114, USA.

Hao D Trieu (HD)

Mongan Institute, Massachusetts General Hospital, Harvard Medical School, 100 Cambridge Street, Suite 1600, Boston, MA, 02114, USA.

Kelly Irwin (K)

Mongan Institute, Massachusetts General Hospital, Harvard Medical School, 100 Cambridge Street, Suite 1600, Boston, MA, 02114, USA.
Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA.

Elizabeth Cella (E)

Vinfen Corporation, Cambridge, MA, USA.

Bruce Bird (B)

Vinfen Corporation, Cambridge, MA, USA.

Kim Shellenberger (K)

Vinfen Corporation, Cambridge, MA, USA.

Paula Silverman (P)

Vinfen Corporation, Cambridge, MA, USA.

Joey Batson (J)

Vinfen Corporation, Cambridge, MA, USA.

Ahmed Fathi (A)

Vinfen Corporation, Cambridge, MA, USA.

Stefanie Gamse (S)

Vinfen Corporation, Cambridge, MA, USA.

Jessica Wolfe (J)

Vinfen Corporation, Cambridge, MA, USA.

Sibyl Holland (S)

Vinfen Corporation, Cambridge, MA, USA.

Karen Donelan (K)

Mongan Institute, Massachusetts General Hospital, Harvard Medical School, 100 Cambridge Street, Suite 1600, Boston, MA, 02114, USA.
Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Ronita Samuels (R)

Mongan Institute, Massachusetts General Hospital, Harvard Medical School, 100 Cambridge Street, Suite 1600, Boston, MA, 02114, USA.

Jessica E Becker (JE)

Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA.

Kenneth A Freedberg (KA)

Mongan Institute, Massachusetts General Hospital, Harvard Medical School, 100 Cambridge Street, Suite 1600, Boston, MA, 02114, USA.
Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Division of General Internal Medicine, Massachusetts General Hospital, Boston, MA, USA.

Jean-Louise Reichman (JL)

North Suffolk Mental Health Association, Chelsea, MA, USA.

Terina Keller (T)

Bay Cove Human Services, Boston, MA, USA.

Alexander C Tsai (AC)

Mongan Institute, Massachusetts General Hospital, Harvard Medical School, 100 Cambridge Street, Suite 1600, Boston, MA, 02114, USA.
Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA.

John Hsu (J)

Mongan Institute, Massachusetts General Hospital, Harvard Medical School, 100 Cambridge Street, Suite 1600, Boston, MA, 02114, USA.
Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Department of Health Care Policy, Harvard Medical School, Boston, MA, USA.

Brian G Skotko (BG)

Down Syndrome Program, Division of Medical Genetics and Metabolism, Department of Pediatrics, Massachusetts General Hospital, Boston, MA, USA.
Department of Pediatrics, Harvard Medical School, Boston, MA, USA.

Stephen Bartels (S)

Mongan Institute, Massachusetts General Hospital, Harvard Medical School, 100 Cambridge Street, Suite 1600, Boston, MA, 02114, USA.
Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Classifications MeSH